Anthropic Bets on Life Sciences for Its IPO

Anthropic aims to make life sciences a driving force for its next phase of growth. The group already claims six-figure contracts in the pharmaceutical sector, is deploying a dedicated product, and is equipping itself with a laboratory, all while promoting the contribution of AI to biomedical research. This strategy is part of an IPO filing where biology takes center stage.

No AI-designed drug has been approved by the FDA, and optimism varies

To date, no AI-designed drug has received FDA approval. Anthropic published survey results in August indicating that 91% of its staff believe a Nobel-level discovery by AI is likely by 2030. In the same survey, 39% of American adults share this perspective for the 2030 deadline.

Health giants are already paying for Claude, including Lilly

According to Anthropic, nine of the ten largest pharmaceutical companies and eight of the ten largest health companies in the Fortune 500 have each invested at least $100,000 in the company over a recent annual period. The company also cites its collaboration with Lilly, which it describes as a $1.3 trillion-valued company with 50,000 employees who have a Claude Enterprise account. According to Anthropic, over 85% of Lilly's staff actively use the tool.

Laboratory, $400 million acquisition, and hiring to accelerate

This year, Anthropic established a molecular biology laboratory in the Bay Area and acquired the biotech startup Coefficient Bio for $400 million in stock in April. Additionally, the beta version of the Claude Science product appeared in June. The company is currently looking to strengthen its teams in chemistry, experimental biology, and research engineering, with two job postings published at the end of last week offering a salary of $320,000 for scientists specializing in the design and production of antibodies. The board also welcomed Vas Narasimhan, CEO of Novartis, in April, marking a shift towards life sciences.

The S-1 roadmap: accelerating research and attracting industry

Anthropic's already registered S-1 filing precedes an IPO announced to be massive next month. AI could rapidly accelerate scientific innovation and bring treatments closer for major diseases, with biological progress cited as the top expected impact. Anthropic details ambitious plans in life sciences and positions itself as a key player in the next generation of biological and medical research, linking these goals to its mission. The group projects that this direction could expand its growth beyond software engineering tools and promote the use of its most advanced and costly models in an industry accustomed to massive R&D expenditures.

Competition and convictions: Rosalind, Isomorphic Labs, and Amodei's vision

Anthropic's stock is positioned against rival solutions, such as OpenAI with its Rosalind service, or Isomorphic Labs, a Google subsidiary aiming to use AI to develop cancer treatments. Dario Amodei, who was a theoretical physicist before becoming CEO of Anthropic, has long highlighted AI's capabilities in the life sciences sector. In a piece published in September, he recounts his personal experience with cancer and access to new treatments after his father's death, topics already addressed in his 2024 book Machines of Loving Grace. He argues that biology is likely the field where scientific advances are most likely to directly improve quality of life, expressing a desire for AI-enabled research to cure all infectious diseases, eradicate most cancers, and double human life expectancy. Ben Mann, who co-leads the Labs entity at Anthropic, notes that his team is now directing its efforts towards life sciences, realigning Labs' missions with goals similar to those mentioned by Amodei.